AGIO
Price
$32.32
Change
-$1.35 (-4.01%)
Updated
Feb 29, 6:59 PM EST
62 days until earnings call
MCRB
Price
$1.14
Change
-$0.01 (-0.87%)
Updated
Feb 29, 6:59 PM EST
4 days until earnings call
Ad is loading...

Analysis and predictions AGIO vs MCRB

Header iconAGIO vs MCRB Comparison
Open Charts AGIO vs MCRBBanner chart's image
Agios Pharmaceuticals
Price$32.32
Change-$1.35 (-4.01%)
Volume$533.55K
CapitalizationN/A
Seres Therapeutics
Price$1.14
Change-$0.01 (-0.87%)
Volume$2.37M
CapitalizationN/A
View a ticker or compare two or three
AGIO vs MCRB Comparison Chart

Loading...

AGIODaily Signal changed days agoGain/Loss if shorted
 
Show more...
MCRBDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
AGIO vs. MCRB commentary
Mar 01, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGIO is a Hold and MCRB is a StrongBuy.

COMPARISON
Comparison
Mar 01, 2024
Stock price -- (AGIO: $32.32 vs. MCRB: $1.14)
Brand notoriety: AGIO and MCRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGIO: 96% vs. MCRB: 87%
Market capitalization -- AGIO: $1.89B vs. MCRB: $147.35M
AGIO [@Biotechnology] is valued at $1.89B. MCRB’s [@Biotechnology] market capitalization is $147.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $541.24B to $0. The average market capitalization across the [@Biotechnology] industry is $2.59B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGIO’s FA Score shows that 0 FA rating(s) are green whileMCRB’s FA Score has 0 green FA rating(s).

  • AGIO’s FA Score: 0 green, 5 red.
  • MCRB’s FA Score: 0 green, 5 red.
According to our system of comparison, AGIO is a better buy in the long-term than MCRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGIO’s TA Score shows that 6 TA indicator(s) are bullish while MCRB’s TA Score has 5 bullish TA indicator(s).

  • AGIO’s TA Score: 6 bullish, 4 bearish.
  • MCRB’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, AGIO is a better buy in the short-term than MCRB.

Price Growth

AGIO (@Biotechnology) experienced а +8.53% price change this week, while MCRB (@Biotechnology) price change was +3.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.64%. For the same industry, the average monthly price growth was +16.56%, and the average quarterly price growth was +43.85%.

Reported Earning Dates

AGIO is expected to report earnings on May 02, 2024.

MCRB is expected to report earnings on May 08, 2024.

Industries' Descriptions

@Biotechnology (+5.64% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for AGIO with price predictions.
OPEN
A.I.dvisor published
a Summary for MCRB with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
AGIO($1.89B) has a higher market cap than MCRB($147M). AGIO YTD gains are higher at: 45.128 vs. MCRB (-18.571). MCRB has higher annual earnings (EBITDA): -124.01M vs. AGIO (-384.86M). AGIO has more cash in the bank: 777M vs. MCRB (170M). AGIO has less debt than MCRB: AGIO (72M) vs MCRB (212M). MCRB has higher revenues than AGIO: MCRB (127M) vs AGIO (26.8M).
AGIOMCRBAGIO / MCRB
Capitalization1.89B147M1,287%
EBITDA-384.86M-124.01M310%
Gain YTD45.128-18.571-243%
P/E RatioN/AN/A-
Revenue26.8M127M21%
Total Cash777M170M457%
Total Debt72M212M34%
FUNDAMENTALS RATINGS
AGIO vs MCRB: Fundamental Ratings
AGIO
MCRB
OUTLOOK RATING
1..100
2114
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
58
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
3765
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
503

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AGIO's Valuation (48) in the Biotechnology industry is in the same range as MCRB (58). This means that AGIO’s stock grew similarly to MCRB’s over the last 12 months.

AGIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MCRB (100). This means that AGIO’s stock grew similarly to MCRB’s over the last 12 months.

AGIO's SMR Rating (96) in the Biotechnology industry is in the same range as MCRB (100). This means that AGIO’s stock grew similarly to MCRB’s over the last 12 months.

AGIO's Price Growth Rating (37) in the Biotechnology industry is in the same range as MCRB (65). This means that AGIO’s stock grew similarly to MCRB’s over the last 12 months.

AGIO's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MCRB (100). This means that AGIO’s stock grew similarly to MCRB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGIOMCRB
RSI
ODDS (%)
Bearish Trend 1 day ago
83%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 8 days ago
72%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 11 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
68%
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
AGIODaily Signal changed days agoGain/Loss if shorted
 
Show more...
MCRBDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSCWX29.030.32
+1.11%
Nuveen Small Cap Value R6
PSSJX23.570.16
+0.68%
Principal SmallCap S&P 600 Index J
SUWIX33.320.16
+0.48%
DWS Core Equity Inst
NIOAX12.880.04
+0.31%
Neuberger Berman Intl Small Cap A
RYCFX50.84-1.18
-2.27%
Rydex Biotechnology C

AGIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AGIO has been loosely correlated with CRSP. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if AGIO jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AGIO
1D Price
Change %
AGIO100%
-4.01%
CRSP - AGIO
54%
Loosely correlated
-3.93%
BEAM - AGIO
53%
Loosely correlated
-9.45%
RARE - AGIO
53%
Loosely correlated
-1.93%
NTLA - AGIO
52%
Loosely correlated
-2.07%
ALNY - AGIO
49%
Loosely correlated
-2.67%
More

MCRB and

Correlation & Price change

A.I.dvisor indicates that over the last year, MCRB has been loosely correlated with MDGL. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if MCRB jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MCRB
1D Price
Change %
MCRB100%
-0.87%
MDGL - MCRB
48%
Loosely correlated
-7.25%
RNA - MCRB
44%
Loosely correlated
+20.05%
ORMP - MCRB
42%
Loosely correlated
-3.81%
AGIO - MCRB
40%
Loosely correlated
-4.01%
BCRX - MCRB
38%
Loosely correlated
-1.31%
More